Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cells
Neuro-Oncology · 2025
DOI: 10.1093/neuonc/noaf155 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Rishab Ramapriyan und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Mass General Brigham and Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Meningioma, Immunotherapy, Adoptive, GPI-Linked Proteins, Meningeal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: William G. Markos Fund for Brain Tumor Immunotherapy, Swim Across America, A Shot for Life.
Abstract (Originalsprache)
Background
Meningioma is the most common primary CNS tumor, with high-grade cases exhibiting aggressive behavior, frequent recurrence, and poor prognosis. Currently, no systemic therapies are approved for recurrent or malignant meningiomas. Chimeric antigen receptor (CAR) T-cell therapy has shown efficacy in hematologic malignancies and promise for solid tumors, but its use for meningiomas has been underexplored. Mesothelin, a glycoprotein overexpressed in several solid tumors of mesodermal origin, may serve as a viable immunotherapeutic target. This study aimed to evaluate mesothelin as a CAR T-cell target in meningiomas.
Methods
Mesothelin expression was analyzed in patient-derived meningioma samples using immunohistochemistry, flow cytometry, and droplet digital PCR. Mesothelin-specific CAR T-cells were generated and evaluated invitro, exvivo using patient-derived organotypic tumor spheroids (PDOTS), and invivo using orthotopic meningioma mouse models of human xenografts. Cytotoxicity, T-cell proliferation, cytokine secretion, and tumor clearance were assessed.
Results
Mesothelin was detected in a subset of tumors across all meningioma grades at the transcript and protein levels, with surface expression confirmed in patient-derived primary cells. Mesothelin-specific CAR T-cells exhibited potent and specific cytotoxicity, T-cell activation, and cytokine secretion in vitro and effectively eliminated PDOTS. In orthotopic human xenograft models, mesothelin CAR T-cell therapy led to significant tumor regression and prolonged survival.
Conclusions
Mesothelin is a viable CAR T-cell target for meningiomas, and mesothelin-specific CAR T-cell therapy shows strong preclinical efficacy. These findings provide a rationale for early-phase clinical trials of mesothelin CAR T-cell therapy in patients with refractory meningiomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Mass General Brigham and Harvard Medical School, Boston, Massachusetts, USA.
- Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Mass General Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
ORCID-Profile: Leonora Balaj, Hiroaki Wakimoto, Joshua D Bernstock, Jorg Dietrich, Marcela V Maus, Bryan D Choi
Förderung
- William G. Markos Fund for Brain Tumor Immunotherapy
- Swim Across America
- A Shot for Life
- Edward S. Toole Glioblastoma Research Fund
- Neurosurgery Research and Education Foundation
- National Brain Tumor Society
- NCI NIH HHS
- The Jenny Fund in honor of Jen Gureckis
Zitieren
APA
Ramapriyan, R., Barker, F. G., Richardson, L. G., Sun, J., Vandecandelaere, G., Shim, J. M., De Vlaminck, G., Gaffey, M., Grewal, E. P., Tazhibi, M., Morshedy, K., Aref, A. R., Batool, S. M., Guo, X., Ijad, N., Balaj, L., Wakimoto, H., Martinez-Lage, M., Frigault, M. J., …, & Choi, B. D. (2025). Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cells. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf155
Vancouver
Ramapriyan R, Barker FG, Richardson LG, Sun J, Vandecandelaere G, Shim JM, et al. Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cells. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf155
BibTeX
@article{Ramapriyan2025,
author = {Ramapriyan, Rishab and Barker, Fred G and Richardson, Leland G and Sun, Jing and Vandecandelaere, Gust and Shim, Jane M and De Vlaminck, Guillaume and Gaffey, Matthew and Grewal, Eric P and Tazhibi, Masih and Morshedy, Kourosh and Aref, Amir R and Batool, Syeda M and Guo, Xiaopeng and Ijad, Nazanin and Balaj, Leonora and Wakimoto, Hiroaki and Martinez-Lage, Maria and Frigault, Matthew J and Leick, Mark B and Bernstock, Joshua D and Bi, Wenya Linda and Carter, Bob S and Chiocca, E Antonio and Dietrich, Jorg and Gerstner, Elizabeth R and Boland, Genevieve M and Nahed, Brian V and Plotkin, Scott R and Jenkins, Russell W and Brastianos, Priscilla K and Curry, William T and Maus, Marcela V and Choi, Bryan D},
title = {Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cells},
journal = {Neuro-Oncology},
year = {2025},
doi = {10.1093/neuonc/noaf155}
}
EUVIMED